London: The Oxford-AstraZeneca vaccine, whose Indian version is Covishield, is going through a rough phase. After 8 European nations temporarily suspended the vaccine due to possible blood clots, countries like Thailand are delaying its rollout.
The European Union’s drug regulator has now recommended adding severe allergy (anaphylaxis and hypersensitivity) as possible side effects.
This is based on 41 reports of possible anaphylaxis from around 5 million vaccinations in the UK.
It is important to note that the European Medicines Agency (EMA) is investigating the development of blood clots post vaccination, that prompted Italy, Norway and Denmark to suspend the jab. EMA, however, added that the vaccine is safe for use.
Anaphylaxis is known to be a common reaction to vaccines. The AstraZeneca shot carries a label that advises patients be kept under close observation for 15 minutes.
Also Read: Eight EU Nations Stop Using AstraZeneca Vaccine
Stay ahead with Odisha Bytes Breaking News - your ultimate source for the fastest, most… Read More
Bhubaneswar: The Odisha Police Recruitment Board (OPRB) has postponed the upcoming examination for Group B… Read More
Bhubaneswar: The Supreme Court Collegium has recommended the appointment of Justice Harish Tandon as the… Read More
Bhubaneswar: Two senior IAS officers of Odisha cadre – Ranjana Chopra and Santosh Kumar Sarangi… Read More
Bhubaneswar: Skygazers are in for a treat as the spectacular total lunar eclipse, also known… Read More
Lucknow: An ‘active terrorist’ of Babbar Khalsa International (BKI), who allegedly has ties with Pakistan’s… Read More
This website uses cookies.